Send feedback

TP53 p.Ser127Pro

c.379T>C · rs1597371694 · VCV934410

Likely pathogenic Expert panel
Classification
Likely pathogenic
ClinVar
Review
Expert panel ★★★☆
ClinVar · 5 submitters
AlphaMissense
likely pathogenic
0.9962 · ACMG-weighted
gnomAD v4.1
Absent
absent from gnomAD v4.1
Missense predictors
3/3 damaging
AlphaMissense, REVEL, SaProt
Conditions
2
Li-Fraumeni syndrome

ClinGen expert panel — TP53 VCEP

Likely Pathogenic for Li-Fraumeni syndrome. Applied ACMG criteria (verbatim):

PP3_Moderate PM2_Supporting PS3 PM1_Supporting PP4

Curation rationale (ClinGen, verbatim)

The NM_000546.6(TP53):c.379T>C variant in TP53 is a missense variant predicted to cause substitution of serine by proline at amino acid 127 (p.Ser127Pro). Although this variant has been observed in germline cases, to our knowledge, this variant has not been reported in individuals meeting classical LFS or Chompret criteria (PS4 not met; Internal lab contributors). At least one individual with this variant was found to have a variant allele fraction of 5-35%, which is a significant predictor of variant pathogenicity (PP4, PMID: 34906512, Internal lab contributor). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity by the majority of available assays indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965, 39774325). Computational predictor scores (BayesDel = 0.58628; Align GVGD = Class C65) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of 65), evidence that correlates with impact to TP53 via protein change (PP3_Moderate). This variant has 4 somatic occurrences for the same amino acid change in cancerhotspots.org (v2) sufficient to be defined as a mutational hotspot by the Clingen TP53 VCEP (2-9 somatic occurrences, PMID: 30311369) (PM1_Supporting). In summary, this variant meets the criteria to be classified as likely pathogenic for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: PP4, PS3, PP3_moderate, PM1_supporting, PM2_supporting. (Bayesian Points: 9; VCEP specifications version 2.4)

ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.

Computational evidence

Protein change
AlphaMissense0.9962likely pathogenic ✓ concordant with ClinVar · top 6% in TP53
REVEL0.957strongly pathogenic-leaning
SaProtLLR -17.06damaging
⇒ AlphaMissense, REVEL and SaProt all call this damaging.
Splicing
SpliceAI—not assessed · no allele here is in the release
Constraint at this position
ConservationphyloP 11GERP 2.5, phastCons 1
Regional constrainto/e 0.89unconstrained · MANE · 6,982 bp · p 0.0085 · regional, not allelic
Overall
CADD25.3PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

Variant & gene context

Gene
TP53
Protein
p.Ser127Pro
Coding
c.379T>C
MANE Select
NM_000546
dbSNP
rs1597371694
Type
single nucleotide variant
Location
chr17:7675233 (GRCh38)
Gene constraint
LOEUF 0.449 · pLI 1.00 · ClinGen HI 3/3 (gnomAD)
Structure
AlphaFold pLDDT 75.83 · 321 PDB
Residue 127
a DNA-binding region; the 'interaction with axin1' region; a β-strand; the 'interaction with ccar2' region; a UniProt-annotated variant site (in a sporadic cancer; somatic mutation); a UniProt-annotated variant site (in sporadic cancers; somatic mutation); the 'interaction with hipk1' region; the 'required for interaction with znf385a' region; the 'required for interaction with fbxo42' region
Full TP53 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

Li-Fraumeni syndrome — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: hereditary neoplastic syndrome

For Li-Fraumeni syndrome (Orphanet):

Inheritance
Autosomal dominant
Onset
All ages
Prevalence
1-9 / 100 000 (United Kingdom)

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/tp53-p-ser127pro (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown